Phyrago™ is an FDA-approved prescription medication used to treat adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML) and Philadelphia chromosome-positive lymphoblastic leukemia (Ph+ALL).
Flex Pharma’s innovative ElectroNanoSpray™ (ENS) technology allows manufacturers of Phyrago™ to provide a next-generation formulation of dasatinib that addresses the current limitations associated with Sprycel® (and its generics). Phyrago™ has pH-independent absorption and is bioequivalent to Sprycel® at the same administered doses, thereby addressing the known limitations of Sprycel® while also preventing any dosing confusion for patients and physicians. Phyrago™ is the only dasatinib therapy available that can be co-administered with acid reducing agents.